Amy B. Summy - Nov 22, 2024 Form 4 Insider Report for LABCORP HOLDINGS INC. (LH)

Role
EVP, Chief Marketing Officer
Signature
/s/ Sandra D. van der Vaart, Attorney-in-Fact for Amy B. Summy
Stock symbol
LH
Transactions as of
Nov 22, 2024
Transactions value $
-$200,534
Form type
4
Date filed
11/26/2024, 11:06 AM
Previous filing
Apr 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LH Common Stock Options Exercise $677K +4.02K +101.01% $168.52 7.99K Nov 22, 2024 Direct
transaction LH Common Stock Sale -$877K -3.67K -45.95% $238.91 4.32K Nov 22, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LH Non-qualified Stock Options Options Exercise $0 -4.02K -100% $0.00 0 Nov 22, 2024 Common Stock 4.02K $168.52 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price of $238.9055 per share represents a weighted average of sales prices ranging from $238.822 to $239.410 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
F2 Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan.
F3 Represents amounts automatically adjusted based on the final adjustment ratio applied to equity awards in connection with the spin-off of Fortrea Holdings Inc. ("Fortrea") by Labcorp Holdings Inc. ("LHI"), calculated pursuant to the terms of the Employee Matters Agreement by and between LHI and Fortrea.
F4 The option vested in three equal annual installments beginning on the date reflected in this column.

Remarks:

On May 17, 2024, LHI became the successor of Laboratory Corporation of America Holdings ("LCAH") pursuant to LCAH's reorganization into a new holding company structure (the "Reorganization"). The Reorganization resulted in LHI becoming a parent holding company of LCAH but did not alter the proportionate interests of LCAH security holders.